AGY — Allergy Therapeutics Share Price
Last trade - 00:00- £250.24m
- £246.57m
- £59.59m
- 14
- 5
- 100
- 30
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.46 | ||
| Price to Tang. Book | 11.65 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.7 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -99.49% | ||
| Return on Equity | -155.9% | ||
| Operating Margin | -81.83% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 73.72 | 78.2 | 84.33 | 72.77 | 59.59 | 75 | 85 | -2.71% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +102.52 | -59.34 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Allergy Therapeutics plc is a United Kingdom-based integrated specialty pharmaceutical company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum-free immunotherapy vaccines that have the potential to cure disease. The Company sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional ten countries. Its pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA, Bee Venom SCIT, Wasp Venom SCIT, Ragweed MATA MPL, Trees MATA, Trees MATA MPL, Peanut SCIT and others. Its commercial portfolio of products includes Pollinex, Venomil and Acarovac. It operates in Austria, Germany, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom.
Directors
- Peter Jensen NEC
- Manuel Llobet CEO
- Nicolas Wykeman CFO
- Sara Goldsbrough SEC
- Scott Leinenweber NED (49)
- Cheryl Macdiarmid NED (53)
- Babatunde Otulana NID
- Mary Tavener NID (60)
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 1st, 2004
- Public Since
- October 11th, 2004
- No. of Employees
- 635
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 4,766,439,938
- Address
- Dominion Way, WORTHING, BN14 8SA
- Web
- https://www.allergytherapeutics.com/
- Phone
- +44 1903844700
- Auditors
- BDO LLP
Latest News for AGY
Upcoming Events for AGY
Full Year 2024 Allergy Therapeutics PLC Earnings Release
Similar to AGY
4Basebio
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
Bioventix
London Stock Exchange
FAQ
As of Today at 19:12 UTC, shares in Allergy Therapeutics are trading at 5.25p. This share price information is delayed by 15 minutes.
Shares in Allergy Therapeutics last closed at 5.25p and the price had moved by +82.48% over the past 365 days. In terms of relative price strength the Allergy Therapeutics share price has outperformed the FTSE All Share Index by +71.37% over the past year.
The overall consensus recommendation for Allergy Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Allergy Therapeutics does not currently pay a dividend.
Allergy Therapeutics does not currently pay a dividend.
Allergy Therapeutics does not currently pay a dividend.
To buy shares in Allergy Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 5.25p, shares in Allergy Therapeutics had a market capitalisation of £250.24m.
Here are the trading details for Allergy Therapeutics:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: AGY
Based on an overall assessment of its quality, value and momentum Allergy Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Allergy Therapeutics is 16.11p. That is 206.86% above the last closing price of 5.25p.
Analysts covering Allergy Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Allergy Therapeutics. Over the past six months, its share price has outperformed the FTSE All Share Index by +123.72%.
As of the last closing price of 5.25p, shares in Allergy Therapeutics were trading +129.76% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Allergy Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 5.25p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Allergy Therapeutics' management team is headed by:
- Peter Jensen - NEC
- Manuel Llobet - CEO
- Nicolas Wykeman - CFO
- Sara Goldsbrough - SEC
- Scott Leinenweber - NED
- Cheryl Macdiarmid - NED
- Babatunde Otulana - NID
- Mary Tavener - NID